2023 - Research.com Biology and Biochemistry in China Leader Award
Jianming Xu mainly investigates Internal medicine, Cancer research, Soil water, Environmental chemistry and Coactivator. His Internal medicine study integrates concerns from other disciplines, such as Placebo, Endocrinology and Oncology. The Cancer research study combines topics in areas such as Cancer, Metastasis, Mammary tumor, Twist transcription factor and Molecular biology.
His research on Soil water also deals with topics like
Jianming Xu spends much of his time researching Internal medicine, Soil water, Environmental chemistry, Agronomy and Oncology. His research in Internal medicine intersects with topics in Gastroenterology and Endocrinology. Jianming Xu has included themes like Coactivator, Receptor and Nuclear receptor in his Endocrinology study.
He combines topics linked to Rhizosphere with his work on Soil water. His Environmental chemistry research incorporates elements of Organic matter, Biochar, Sorption and Microbial population biology. His studies examine the connections between Cancer and genetics, as well as such issues in Cancer research, with regards to Metastasis and Nuclear receptor coactivator 3.
His primary areas of investigation include Environmental chemistry, Soil water, Internal medicine, Biochar and Soil pH. The study incorporates disciplines such as Nitrification, Microbial population biology, Environmental remediation, Denitrification and Amendment in addition to Environmental chemistry. His biological study spans a wide range of topics, including Rhizosphere, Contamination, Agronomy and Pollution.
Jianming Xu has researched Internal medicine in several fields, including Placebo and Oncology. His research combines Phases of clinical research and Oncology. The Biochar study combines topics in areas such as Arsenic, Manure, Cadmium, Straw and Aqueous solution.
His main research concerns Environmental chemistry, Soil water, Biochar, Cadmium and Soil pH. His Environmental chemistry study combines topics from a wide range of disciplines, such as Amendment, Soil contamination, Nitrification and Environmental remediation. His work carried out in the field of Soil water brings together such families of science as Agriculture, Agronomy and Abundance.
His Biochar study integrates concerns from other disciplines, such as Soil conditioner, Straw, Bioavailability, Bulk soil and Aqueous solution. His study in Cadmium is interdisciplinary in nature, drawing from both Environmental health, Adsorption, Pollution and Arsenic. As a member of one scientific family, he mostly works in the field of Soil pH, focusing on Phosphorus and, on occasion, Nutrient.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Ann Lii Cheng;Yoon Koo Kang;Zhendong Chen;Chao Jung Tsao.
Lancet Oncology (2009)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D Demetri;Peter Reichardt;Yoon-Koo Kang;Jean-Yves Blay.
The Lancet (2013)
Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction
Jin Li;Shukui Qin;Jianming Xu;Jianping Xiong.
Journal of Clinical Oncology (2016)
Partial Hormone Resistance in Mice with Disruption of the Steroid Receptor Coactivator-1 (SRC-1) Gene
Jianming Xu;Yuhong Qiu;Francesco J. DeMayo;Sophia Y. Tsai.
Human health risk assessment of heavy metals in soil–vegetable system: A multi-medium analysis
Xingmei Liu;Qiujin Song;Yu Tang;Wanlu Li.
Science of The Total Environment (2013)
Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial
Ann Lii Cheng;Yoon Koo Kang;Deng Yn Lin;Joong Won Park.
Journal of Clinical Oncology (2013)
Activation of PPARγ coactivator-1 through transcription factor docking
Pere Puigserver;Guillaume Adelmant;Zhidan Wu;Melina Fan.
An essential heparin-binding domain in the fibroblast growth factor receptor kinase
Mikio Kan;Fen Wang;Jianming Xu;John W. Crabb.
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li;Shukui Qin;Rui-Hua Xu;Thomas C C Yau.
Lancet Oncology (2015)
The steroid receptor coactivator SRC-3 (p/CIP/RAC3/AIB1/ACTR/TRAM-1) is required for normal growth, puberty, female reproductive function, and mammary gland development
Jianming Xu;Lan Liao;Guang Ning;Hiromi Yoshida-Komiya.
Proceedings of the National Academy of Sciences of the United States of America (2000)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: